{"drugs":["Cyramza","Ramucirumab"],"mono":{"0":{"id":"930938-s-0","title":"Generic Names","mono":"Ramucirumab"},"1":{"id":"930938-s-1","title":"Dosing and Indications","sub":[{"id":"930938-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Gastric cancer, Monotherapy or in combination with paclitaxel for advanced or metastatic disease, progressing after treatment with fluoropyrimidine- or platinum-containing chemotherapy:<\/b> Monotherapy, 8 mg\/kg IV infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity; premedicate with IV histamine H1 antagonist (eg, diphenhydramine hydrochloride) prior to infusion; if grade 1 or 2 infusion reaction has occurred previously, also give dexamethasone (or equivalent) and acetaminophen<\/li><li><b>Gastric cancer, Monotherapy or in combination with paclitaxel for advanced or metastatic disease, progressing after treatment with fluoropyrimidine- or platinum-containing chemotherapy:<\/b> Combination therapy, 8 mg\/kg IV infusion over 60 minutes every 2 weeks (manufacturer dose) in combination with paclitaxel 80 mg\/m(2) IV infusion on days 1, 8, and 15 every 28 days (study dose) until disease progression or unacceptable toxicity; premedicate with IV histamine H1 antagonist (eg, diphenhydramine hydrochloride) prior to ramucirumab infusion; if grade 1 or 2 infusion reaction has occurred previously, also give dexamethasone (or equivalent) and acetaminophen<\/li><li><b>Malignant neoplasm of cardio-esophageal junction of stomach, Monotherapy or in combination with paclitaxel for advanced or metastatic disease, progressing after treatment with fluoropyrimidine- or platinum-containing chemotherapy:<\/b> Monotherapy, 8 mg\/kg IV infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity; premedicate with IV histamine H1 antagonist (eg, diphenhydramine hydrochloride) prior to infusion; if grade 1 or 2 infusion reaction has occurred previously, also give dexamethasone (or equivalent) and acetaminophen<\/li><li><b>Malignant neoplasm of cardio-esophageal junction of stomach, Monotherapy or in combination with paclitaxel for advanced or metastatic disease, progressing after treatment with fluoropyrimidine- or platinum-containing chemotherapy:<\/b> Combination therapy, 8 mg\/kg IV infusion over 60 minutes every 2 weeks (manufacturer dose) in combination with paclitaxel 80 mg\/m(2) IV infusion on days 1, 8, and 15 every 28 days (study dose) until disease progression or unacceptable toxicity; premedicate with IV histamine H1 antagonist (eg, diphenhydramine hydrochloride) prior to ramucirumab infusion; if grade 1 or 2 infusion reaction has occurred previously, also give dexamethasone (or equivalent) and acetaminophen<\/li><li><b>Metastatic colorectal cancer, In combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), in patients whose disease progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine:<\/b> 8 mg\/kg IV infusion over 60 minutes every 2 weeks (manufacturer dose) prior to  irinotecan 180 mg\/m(2) IV infusion over 90 minutes followed by or concurrent with leucovorin 400 mg\/m(2) IV infusion over 120 minutes, followed by fluorouracil 400 mg\/m(2) IV bolus over 2 to 4 minutes then 2400 mg\/m(2) IV continuous infusion over 48 hours (study dose)  until disease progression or unacceptable toxicity; premedicate with IV histamine H1 antagonist (eg, diphenhydramine hydrochloride) prior to ramucirumab infusion; if grade 1 or 2 infusion reaction has occurred previously, also give dexamethasone (or equivalent) and acetaminophen<\/li><li><b>Non-small cell lung cancer, Metastatic, in combination with docetaxel after progression on or after platinum-based chemotherapy; Adjunct:<\/b> 10 mg\/kg IV infusion over 60 minutes on day 1 (manufacturer dose) prior to docetaxel  75 mg\/m(2) or 60 mg\/m(2) IV infusion (study dose)  every 21 days until disease progression or unacceptable toxicity; premedicate with IV histamine H1 antagonist (eg, diphenhydramine hydrochloride) prior to ramucirumab infusion; if grade 1 or 2 infusion reaction has occurred previously, also give dexamethasone (or equivalent) and acetaminophen<\/li><\/ul>"},{"id":"930938-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients "},{"id":"930938-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> Adjustment not required<\/li><li><b>Hepatic impairment, mild (total bilirubin within ULN and AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN and any AST):<\/b> No adjustment recommended<\/li><li><b>Hepatic impairment, moderate (total bilirubin greater than 1.5 to 3 times ULN and any AST):<\/b> No adjustment recommended<\/li><li><b>Hepatic impairment, Child-Pugh class B or C cirrhosis:<\/b> Clinical deterioration has been reported.<\/li><li><b>Hypertension, severe:<\/b> Interrupt therapy until controlled; permanently discontinue if not controlled with antihypertensive treatment.<\/li><li><b>Infusion-related reactions:<\/b> Grade 1 or 2, reduce the rate of infusion by 50%; grade 3 or 4, permanently discontinue therapy.<\/li><li><b>Urine protein level 2 g\/24 hr or greater (gastric or gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer):<\/b> Interrupt therapy; when level returns to less than 2 g\/24 hr, resume at a reduced dose of 6 mg\/kg every 2 weeks. If level 2 g\/24 hr or greater recurs, interrupt therapy again, and when level returns to less than 2 g\/24 hr, resume at a reduced dose of 5 mg\/kg every 2 weeks.<\/li><li><b>Urine protein level 2 g\/24 hr or greater (non-small cell lung cancer):<\/b> Interrupt therapy. When level returns to less than 2 g\/24 hr, resume at a reduced dose of 8 mg\/kg every 21 days. If level 2 g\/24 hr or greater recurs, interrupt therapy again, and when level returns to less than 2 g\/24 hr, resume at a reduced dose of 6 mg\/kg every 21 days.<\/li><li><b>Urine protein level greater than 3 g\/24 hr or development of nephrotic syndrome (any indication):<\/b> Permanently discontinue therapy.<\/li><li><b>Wound healing complications:<\/b> Prior to scheduled surgery, or if wound healing complications occur during therapy, interrupt ramucirumab until the wound is fully healed.<\/li><\/ul>"},{"id":"930938-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Gastric cancer, Monotherapy or in combination with paclitaxel for advanced or metastatic disease, progressing after treatment with fluoropyrimidine- or platinum-containing chemotherapy<\/li><li>Malignant neoplasm of cardio-esophageal junction of stomach, Monotherapy or in combination with paclitaxel for advanced or metastatic disease, progressing after treatment with fluoropyrimidine- or platinum-containing chemotherapy<\/li><li>Metastatic colorectal cancer, In combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), in patients whose disease progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine<\/li><li>Non-small cell lung cancer, Metastatic, in combination with docetaxel after progression on or after platinum-based chemotherapy; Adjunct<\/li><\/ul>"}]},"2":{"id":"930938-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Ramucirumab increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue ramucirumab in patients who experience severe bleeding. Ramucirumab can also increase the risk of potentially fatal gastrointestinal perforation. Permanent discontinue treatment if this event occurs. Impaired wound healing may occur with antibodies inhibiting the vascular endothelial growth factor pathway. Withhold treatment prior to surgery and discontinue ramucirumab if impaired wound healing or wound healing complications occur.<br\/>"},"3":{"id":"930938-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930938-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined.<br\/>"},{"id":"930938-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warnings:<\/li><li>-- Hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events, have been reported; discontinue use if severe bleeding occurs<\/li><li>-- Gastrointestinal perforation has been reported and may be fatal; discontinue if this occurs<\/li><li>-- Impaired wound healing may occur; discontinue if wound healing complications <\/li><li>-- Surgery; interrupt therapy prior to surgery but may resume following surgery based on clinical judgement of wound healing; discontinue use if wound healing complications occur<\/li><li>Cardiovascular:<\/li><li>--Severe hypertension has been reported; monitoring recommended; interruption or discontinuation may be necessary<\/li><li>Endocrine and Metabolic:<\/li><li>-- Thyroid dysfunction has been reported; monitoring recommended<\/li><li>Hematologic:<\/li><li>-- Arterial thromboembolic events (ATE) which may be serious and sometimes fatal, including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia have been reported; discontinue use if severe ATE occurs<\/li><li>Hepatic:<\/li><li>-- Preexisting cirrhosis (Child-Pugh B or C); clinical deterioration has been reported in these patients; use only if benefits outweigh risks<\/li><li>Neurologic:<\/li><li>-- Reversible posterior leukoencephalopathy syndrome has been reported; if suspected confirm diagnosis with MRI and discontinue use<\/li><li>Renal:<\/li><li>-- Severe proteinuria has been reported; monitoring recommended; dose reduction, interruption, or discontinuation may be required<\/li><li>Reproductive:<\/li><li>-- Drug may cause fetal harm; effective contraception recommended during and for 3 months after therapy<\/li><li>-- Drug may impair fertility<\/li><li>Other:<\/li><li>-- Infusion-related reactions have been reported, some cases were severe; monitoring recommended; dosage adjustment or discontinuation may be required<\/li><\/ul>"},{"id":"930938-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"930938-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930938-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, All grades (Monotherapy, 16%; combination therapy, 11% to 26%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (Monotherapy, 14%; combination therapy, 32% to 60%)<\/li><li><b>Hematologic:<\/b>Neutropenia, All grades (Monotherapy, 4.7%; combination therapy, 54% to 59%)<\/li><li><b>Respiratory:<\/b>Epistaxis (Monotherapy, 4.7%; combination therapy, 19% to 33%)<\/li><li><b>Other:<\/b>Fatigue<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Grade 3 or higher (Monotherapy, 8%; combination therapy, 6% to 15%)<\/li><li><b>Dermatologic:<\/b>Impaired wound healing<\/li><li><b>Gastrointestinal:<\/b>Bowel obstruction (Monotherapy, 2.1%), Gastrointestinal hemorrhage (Combination therapy, 10% to 12%), Gastrointestinal perforation (Monotherapy, 0.7% to 0.8%; combination therapy, 1% to 1.2%)<\/li><li><b>Hematologic:<\/b>Anemia (Monotherapy, 3.8%), Arterial thromboembolism (Monotherapy, 1.7%), Febrile neutropenia (Combination therapy, 2.4% to 16%), Hemorrhage, Severe (2.5% to 4.3%), Neutropenia, Grade 3 or higher (Combination therapy, 38% to 49%)<\/li><li><b>Hepatic:<\/b>Cirrhosis of liver, Clinical deterioration<\/li><li><b>Immunologic:<\/b>Infusion reaction (With premedication, 0.4%)<\/li><li><b>Neurologic:<\/b>Posterior reversible encephalopathy syndrome (Monotherapy, less than 0.1%)<\/li><li><b>Renal:<\/b>Nephrotic syndrome, Proteinuria (Monotherapy, 8%; combination therapy, 3.3% to 17%)<\/li><\/ul>"},"6":{"id":"930938-s-6","title":"Drug Name Info","sub":{"0":{"id":"930938-s-6-17","title":"US Trade Names","mono":"Cyramza<br\/>"},"2":{"id":"930938-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"930938-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930938-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930938-s-7","title":"Mechanism Of Action","mono":"Ramucirumab is vascular endothelial growth factor (VEGF) receptor 2 antagonist that inhibits ligand-stimulated activation of the VEGF receptor 2, ligand-induced proliferation, and migration of human endothelial cells.<br\/>"},"8":{"id":"930938-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930938-s-8-24","title":"Distribution","mono":"Vd: 5.5 to 7.1 L <br\/>"},"3":{"id":"930938-s-8-26","title":"Excretion","mono":"Total body clearance: 0.015 L\/hr <br\/>"},"4":{"id":"930938-s-8-27","title":"Elimination Half Life","mono":"14 days <br\/>"}}},"9":{"id":"930938-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Dilute only with NS; do not dilute with other solutions, including dextrose-containing solutions.<\/li><li>Withdraw the volume of ramucirumab for the required dose and dilute with NS to a final volume of 250 mL.<\/li><li>Discard any unused portion of the vial.<\/li><li>Gently invert to mix; do not shake.<\/li><li>Do not freeze; use diluted solution within 24 hours if stored 2 to 8 degrees C (36 to 46 degrees F) or within 4 hours if stored at room temperature, below 25 degrees C (77 degrees F).<\/li><li>Only administer by IV infusion; do not give as IV push or bolus.<\/li><li>Do not co-infuse with other electrolytes or drugs.<\/li><li>Infuse over 60 minutes, through a separate infusion line using an infusion pump; a protein-sparing 0.22 micron filter is recommended.<\/li><li>Flush line with NS at the conclusion of the infusion.<\/li><\/ul>"},"10":{"id":"930938-s-10","title":"Monitoring","mono":"<ul><li>An objective reduction in tumor size<\/li><li>Proteinuria by dipstick urine analysis or urinary protein-creatinine ratio; during therapy;  24-hour urine collection for a urine dipstick reading of 2+<\/li><li>Thyroid function; during therapy<\/li><li>Blood pressure; at least every 2 weeks (more often if indicated)<\/li><li>Signs and symptoms of infusion-related reactions<\/li><\/ul>"},"11":{"id":"930938-s-11","title":"How Supplied","mono":"<b>Cyramza<\/b><br\/>Intravenous Solution: 10 MG\/ML<br\/>"},"13":{"id":"930938-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report symptoms of bleeding or gastrointestinal perforation.<\/li><li>Warn patient to report symptoms of severe hypertension, myocardial infarction, or stroke.<\/li><li>Tell female patient to avoid pregnancy during therapy and for at least 3 months after the last dose.<\/li><li>Counsel patient that drug may impair wound healing and to discuss use with physician prior to surgery.<\/li><li>Side effects may include fatigue, asthenia, stomatitis, mucosal inflammation, anorexia, diarrhea, epistaxis, rash, and infusion-related reactions.<\/li><li>Counsel female patient that drug may cause infertility.<\/li><\/ul>"}}}